Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2005
11/09/2005EP1019392B1 Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
11/09/2005EP1019389B1 Epothilone derivatives
11/09/2005EP0988285B1 Prodrug forms of ribonucleotide reductase inhibitors 3-ap and 3-amp
11/09/2005EP0971745B1 Gel delivery vehicles for anticellular proliferative agents
11/09/2005EP0960192B1 Synthetic polynucleotides
11/09/2005EP0917569B1 Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
11/09/2005EP0844874B1 METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ALPHA v BETA 5 MEDIATED ANGIOGENESIS
11/09/2005EP0772455B1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
11/09/2005EP0751992B1 Vascular endothelial growth factor 2
11/09/2005CN1695059A Method of diagnosing colon and gastric cancers
11/09/2005CN1694902A Methods for regulating cancer
11/09/2005CN1694901A Kdr peptides and vaccines comprising the same
11/09/2005CN1694900A EE3-protein family and corresponding DNA sequences
11/09/2005CN1694886A Novel imidazopyrazines as cyclin dependent kinase inhibitors
11/09/2005CN1694879A Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
11/09/2005CN1694864A N-bridged selective androgen receptor modulators and methods of use thereof
11/09/2005CN1694736A Medical devices containing rapamycin analogs
11/09/2005CN1694719A Casein derived peptides and uses thereof in therapy
11/09/2005CN1694713A Stable oxazaphosphorine-2-mercaptoethanesulphonate formulations
11/09/2005CN1694705A Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
11/09/2005CN1694691A Treatment of metastatic breast cancer with anthracyclines and taxanes
11/09/2005CN1694690A Combination chemotherapy compositions and methods
11/09/2005CN1226412C Deactivated protein gene in ribosome of motherwort
11/09/2005CN1226410C CR1 gene related to cell reconstitution, conduction and death
11/09/2005CN1226305C Protein extracted from perinereis aibuhitensis, its preparation method and use
11/09/2005CN1226041C Anti-cancer Chinese medicine formula
11/08/2005US6963011 Central nervous system disorders; psychological disorders
11/08/2005US6963010 Hydrophobic polyamine analogs and methods for their use
11/08/2005US6962996 Inhibitors of p38
11/08/2005US6962993 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/08/2005US6962978 Multiple sclerosis; immobilization; water solubility
11/08/2005US6962969 Compounds and methods for modulating nonclassical cadherin-mediated functions
11/08/2005US6962944 Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
11/08/2005US6962941 such as 1,4-Bis-{N-[3-(3-aminomethylphenylproplonyl)-2-methoxycarbonylpyrrolidin-4-yl]aminocarbonyloxy}-2-butyne dihydrochloride; for treatment of asthma, allergic conjunctivitis, allergic rhinitis, psoriasis, and ulcerative colitis
11/08/2005US6962940 Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders
11/08/2005US6962938 Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)
11/08/2005US6962937 Imidazolidine derivatives, their preparation and their use
11/08/2005US6962936 Treating diseases such as cancer, inflammatory disorders, restenosis,
11/08/2005US6962929 Drugs such as 4-(N,N-Dimethylamino)-1-pentafluorophenyl-sulfonamidobenzene and/or prodrugs, used as anticarcinogenic agents, microbiocides or bactericides; tubulin inhibitors
11/08/2005US6962928 such as 6-methoxy-2-(4-methoxyphenyl)-1-[4-(2-piperidin-1-yl-ethyoxy)-phenyl]-1,2,3,4-tetrahydroquinoline
11/08/2005US6962923 Pyrazole compositions
11/08/2005US6962918 Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
11/08/2005US6962915 Antiinflammatory agents
11/08/2005US6962912 Substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them
11/08/2005US6962908 Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
11/08/2005US6962803 Using corynebacterium to ferment diphtheria toxin and treat neoplasms of central nervous system; antitumor agents
11/08/2005US6962799 Microtubule-associated proteins and tubulins
11/08/2005US6962792 cyclin-dependent kinase 4 (CDK4); useful in treatment of tumours and other hyperproliferative disorders
11/08/2005US6962720 Triterpene compositions and methods for use thereof
11/08/2005US6962694 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
11/08/2005CA2297294C Phosphonomethoxymethylpurine/pyrimidine derivatives
11/08/2005CA2251690C New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
11/08/2005CA2195677C Endothelin antagonists
11/08/2005CA2157288C Methods and compositions for inhibition of angiogenesis
11/06/2005CA2504403A1 Prognostic for hematological malignancy
11/03/2005WO2005103257A1 GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA
11/03/2005WO2005103250A1 THERAPEUTIC MEDICINE CONTAINING MONOCLONAL ANTIBODY AGAINST FOLATE RECEPTOR BETA (FR-β)
11/03/2005WO2005103237A1 Method of constructing recombinant herpes simplex virus
11/03/2005WO2005103088A1 A single-domain antibody strengthening fusion protein vh-ldp-ae
11/03/2005WO2005103071A1 Peptide inhibitors of metalloproteinase activity
11/03/2005WO2005103015A1 Triazine compounds and their analogs, compositions, and methods
11/03/2005WO2005103014A1 2,4-dioxo-5-(2-hydroxy-3,5-dichloro-benzylidene)imino-1,3-pyrimidine salts
11/03/2005WO2005103012A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof
11/03/2005WO2005102981A1 Novel compounds and medicinal use thereof
11/03/2005WO2005102388A1 Novel blt2-mediated disease, and blt2 binding agent and compound
11/03/2005WO2005102381A1 Bone densifying agent characterized by use of cathepsin k inhibitor with pth
11/03/2005WO2005102369A1 Pharmaceutical preparation containing bacterial cell wall skeleton component
11/03/2005WO2005102312A1 Concentrated oxaliplatin solutions
11/03/2005WO2005102302A1 Medicinal preparation
11/03/2005WO2005102301A2 Hydroxymethylbutyrate compositions and uses thereof
11/03/2005WO2005082079A3 Tetracyclic lactam derivatives and uses thereof
11/03/2005WO2005002555A3 Sirt1 modulators for manipulating cell/organism lifespan/stress response
11/03/2005WO2005000240A3 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
11/03/2005WO2004093916A8 A medicament for the two-step perioperative therapy of solid tumours
11/03/2005US20050245736 Low molecular weight oversulfated polysaccharide
11/03/2005US20050245602 Selective estrogen receptor modulators
11/03/2005US20050245598 Antiproliferative activity and is most unlikely a substrate for P-glycoprotein and/or Multidrug Resistant Protein
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245586 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12
11/03/2005US20050245575 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
11/03/2005US20050245570 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
11/03/2005US20050245564 Methods and compositions related to IRM compounds and toll-like receptor pathways
11/03/2005US20050245562 1h-imidazo[4,5-c]quinoline derivatives in the treatment of protein kinase dependent diseases
11/03/2005US20050245561 Anti-tumour polycyclic carboxamides
11/03/2005US20050245549 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
11/03/2005US20050245545 administering a xanthine derivative such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
11/03/2005US20050245538 Dipeptidyl peptidase inhibitor; antidiabetic agents; obesity; viricides; anticancer agents; oral diseases; autoimmune disease
11/03/2005US20050245537 Use of compounds having ccr antagonism
11/03/2005US20050245530 Monocyclic heterocycles as kinase inhibitors
11/03/2005US20050245527 Nitrogen containing heterocyclic compounds and medicines containing the same
11/03/2005US20050245525 Compounds useful for inhibiting CHK1
11/03/2005US20050245523 Heteroaryl derivatives and their use as medicaments
11/03/2005US20050245514 Novel physiologically active substances
11/03/2005US20050245511 Novel compounds that inhibit tryptase activity
11/03/2005US20050245491 Tetracycline derivatives and methods of use thereof
11/03/2005US20050245490 Chromene-containing compounds with anti-tubulin and vascular targeting activity
11/03/2005US20050245488 Pharmaceutically active compounds and methods of use thereof
11/03/2005US20050245486 Prostate specific membrane antigen (PSMA); for diagnosis, detection and treatment of cancer; gene overexpression; kits
11/03/2005US20050245471 Combination products for use in antitumoral treatment
11/03/2005US20050245466 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
1 ... 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 ... 2211